Kynmobi® (apomorphine hydrochloride) is a prescription sublingual film (placed under the tongue) used to treat short-term (acute), intermittent “off” episodes in people with Parkinson’s disease (PD).
As of June 27, 2022, BC PharmaCare's Special Authority program will cover Kynmobi for patients with advanced Parkinson’s disease and the following criteria are met:
- Prescribed by a neurologist or internal medicine specialist with experience in the diagnosis and management of Parkinson’s disease
- Used as adjunctive therapy in patients who are receiving optimized Parkinson’s disease therapy (levodopa and derivatives and other adjunctive Parkinson's medications) that are still experiencing "off" episodes
Special Authority (SA) grants coverage to a drug, medical supply, or device that otherwise would not be eligible for full coverage. Coverage is provided to patients in specific medical circumstances and depends on the patient’s PharmaCare plan rules, including deductible requirements. Special Authority requests must be made by a prescriber. Coverage is approved for patients who meet established criteria. In exceptional circumstances, SA may grant PharmaCare coverage to patients who don’t meet the pre-defined criteria, or for non-benefit items.
More specific information, including special authority request forms, is available here.